{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
NCT01782664: Phase 2 Interventional Completed Psoriasis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Solcitinib (also known as GSK2586184 or GLPG0778) is a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriasis, lupus, and ulcerative colitis. Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. It was reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect. And an exploratory Phase I/II of the same drug for ulcerative colitis was put on hold as investigators review the program.
Status:
Investigational
Source:
Antimicrob Agents Chemother. May 2022;66(5):e0139921.: Phase 3 Human clinical trial Completed Pneumonia, Ventilator-Associated
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02278133: Phase 1/Phase 2 Interventional Completed Metastatic Colorectal Cancer
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Novartis Oncology (previously Novartis) is developing WNT-974 (formerly LGK 974), a first-in-class selective small molecule inhibitor of O-acyltransferase. WNT-974 is under development for the treatment of cancers that are driven by the Wnt pathway in a Wnt ligand-dependent manner. Upon oral administration, WNT-974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT01404585: Phase 2 Interventional Completed Rheumatoid Arthritis
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01408667: Phase 1/Phase 2 Interventional Completed Metabolic Cardiovascular Syndrome
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
TRC-150094 is a synthetic compound that displays the capacity to stimulate energy expenditure. TRC-150094 increases whole body energy expenditure, increases mitochondrial fatty acid oxidation (FAO), and reduces abdominal adiposity in rats fed a high-fat diet. TRC-150094 attenuates the progression of hypertension, insulin resistance, dysglycemia, and atherogenic dyslipidemia, factors reported to signify significant cardiovascular (CV) risk amongst viscerally obese dysglycemic subjects. Moreover, at organ level, TRC150094 reduced steatohepatitis, reduced progression of nephropathy, and preserved cardiac contractile function. Pharmacological profile of TRC-150094 may constitute a promising new class of molecules that may have a potential beneficial therapeutic approach for the treatment of nontraditional CV risk factors and may reduce residual risk in viscerally obese dysglycemic patients. Moreover, the observed metabolic and functional effects on skeletal muscle suggest that TRC-150094 as a therapy may help to facilitate adherence to prescribed exercise, which would remain the mainstay along with diet control in such patients. Simultaneous systemic administration of TRC-150094 to rats receiving an high-fat diet results in a reduction in fat accumulation within the liver and a marked reduction in adipose tissue mass. TRC-150094 is in phase-III clinical trials for the treatment of diabetes mellitus, hypertension and dyslipidaemias (adjunctive treatment) in India.
Status:
Investigational
Source:
NCT02232646: Phase 2 Interventional Withdrawn Urologic Malignancies
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Amcasertib is an orally administered investigational agent designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases. Amcasertib is undergoing multiple Phase I and Phase II studies as monotherapy and combination therapy for treating a range of tumor types.
Status:
Investigational
Source:
NCT04528758: Early Phase 1 Interventional Suspended Coronary Artery Disease
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
JAN:HYOSCYAMINE METHYLBROMIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Hyoscyamine methylbromide, a muscarinic acetylcholine receptor antagonist, was studied as an antispasmodic.
Status:
Investigational
Source:
NCT04442945: Phase 1 Interventional Completed Healthy
(2020)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
